The Independent Payment Advisory Board was supposed to make it easier for Congress to control Medicare spending. But Congress never loved it. Now it's gone.
Mr. Azar, a former drug company executive, immediately confronts two huge challenges: how to rein in drug prices and how to administer the Affordable Care Act.
The Trump administration has unveiled a Medicare program that closely resembles the Obama-era efforts to change the way doctors and hospitals are paid.